Project Grant R01HL173186

Award Date 12/12/24
Completion Date 11/30/28
Dollars Obligated $742K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $810,650 to Cedars-Sinai Medical Center to develop and validate an artificial intelligence (AI)-enabled system for characterizing fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and risk of mortality and stroke following...
This $756,895 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop and validate a precision genetic testing approach guided by machine learning (ML) algorithms for improved diagnosis of hypertrophic cardiomyopathy (HCM) and transthyretin amyloidosis (ATTR-CM). The key products/services to be delivered include: Refinement, validation, and testing of a deep learning (DL) algorithm for HCM and ATTR-CM detection...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $129,612 to Case Western Reserve University to develop new AI methods for analyzing coronary computed tomography angiography (CCTA) images. The goal is to identify imaging features in CCTA that correlate with high-risk coronary atherosclerotic plaques as detected by the gold-standard...
This Project Grant from the National Institute for Minority Health and Health Disparities, part of the Department of Health and Human Services National Institutes of Health, provides $769,755 to develop an unbiased machine learning tool for the prediction of acute coronary syndrome. The tool aims to minimize bias in predictions between patient demographic groups, as measured by equal opportunity difference and the Zemel statistic, to ensure machine learning algorithms do not exacerbate...
This $569,891.83 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project to develop computational models that can predict the risk of heart failure after a myocardial infarction (MI). The project aims to refine and validate a framework for subject-specific cardiac growth and remodeling models, and to quantify the propensity for adverse cardiac remodeling and identify risk factors...
This federal Project Grant award of $704,611, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate a deep learning model called EchoNext that can accurately detect undiagnosed structural heart disease from electrocardiogram (ECG) data. The project, titled "Capitalizing on Artificial Intelligence to Capture Undiagnosed Structural Heart Disease from Electrocardiograms (CACTUS)",...
This $223,750 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to leverage advanced medical image processing and computational modeling methods to gain sex-specific insights into cardiac remodeling and dysfunction in women with severe aortic stenosis (AS). The research objectives are to: Develop an automated pipeline to segment clinical images, create statistical shape analysis models to extract...
The University of California, Davis received a 5-year, $1,738,092 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on heart failure with preserved ejection fraction (HFpEF). The funding will enable the development of computational models and conduct experimental studies to identify key molecular and cellular changes in HFpEF, explore the impact of phenotypic heterogeneity on disease...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $750,406 to develop novel data-driven motion corrected direct 4D parametric image reconstruction techniques integrating unsupervised deep learning-based regularization. The objective is to reduce noise and maintain quantitative accuracy in dynamic 82Rb PET myocardial perfusion (MP) imaging. The proposed methods will be validated using large...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $540,771 to the Denver Health and Hospital Authority to develop an innovative, socially-conscious machine learning-based tool for personalized stroke risk stratification among patients with atrial fibrillation. The central goal is to leverage large datasets, including social determinants of health data, to discover new clinical and...

RADIOMICS-BASED RISK PREDICTION OF HEART FAILURE USING CT CALCIUM SCORE EXAM - RADIOMICS-BASED RISK PREDICTION OF HEART FAILURE USING CT CALCIUM SCORE EXAM PROJECT SUMMARY HEART FAILURE (HF) IS A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN THE UNITED STATES. THERE IS A COMPELLING NEED FOR PERSONALIZED PRE-EMPTIVE HF RISK PREDICTION TO FACILITATE PRECISE PREVENTIVE STRATEGIES TO ALLEVIATE THE POPULATION BURDEN. HOWEVER, CURRENTLY, THERE ARE NO WIDELY VALIDATED MODELS FOR HF RISK PREDICTION, WHICH HINDERS THE TIMELY IDENTIFICATION OF A PRE-EMPTIVE INITIATION OF THERAPIES IN AT-RISK PATIENTS. NON-CONTRAST LOW-DOSE CT SCANS FOR CORONARY ARTERY CALCIUM SCORING (CT CALCIUM SCORING, CTCS), ALREADY WIDELY UTILIZED FOR RISK ASSESSMENT IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, OFFER AN OPPORTUNITY TO IDENTIFY KEY PATHOPHYSIOLOGIC PATHWAYS CAUSALLY OR CONSEQUENTIALLY LINKED WITH HF RISK. THE CENTRAL PREMISE OF THIS TRANSFORMATIVE PROPOSAL IS THAT A RELIABLE AND REPRODUCIBLE CTCS-BASED HF-SPECIFIC CLINICO-RADIOMIC RISK MODEL (CTCSHF) WILL ENABLE THE PRECISION IDENTIFICATION OF PATIENTS AT RISK FOR HF. WE WILL LEVERAGE THE UNIVERSITY HOSPITALS CLARIFY PROGRAM, THE WORLD'S LARGEST FREE CTCS PROGRAM (>100K UNIQUE PARTICIPANTS WITH ~15K INCREASE PER YEAR AND > 3000 HF EVENTS) AND OUR HOUSTON METHODIST HEARTSCAN CTCS PROGRAM (> 50K UNIQUE PARTICIPANTS WITH ~10K INCREASE PER YEAR AND ~2K HF EVENTS) IN ADDITION TO 2 EXTERNAL PROSPECTIVE NIH-FUNDED COHORTS (CARDIA AND CRIC), THAT TOGETHER WILL PROVIDE A ROBUST OPPORTUNITY FOR MODEL DERIVATION AND VALIDATION. TOGETHER WITH INSTITUTIONAL EXPERTISE IN COMPUTATIONAL IMAGE ANALYSIS AND CARDIOVASCULAR IMAGING, WE WILL DEVELOP AND VALIDATE A COMPREHENSIVE MACHINE LEARNING BASED ANALYSIS OF CTCS TO IDENTIFY KEY IMAGE-BASED BIOMARKERS (RADIOMICS) CORRESPONDING TO 5 PATHOPHYSIOLOGIC DOMAINS LINKED WITH HF RISK. THEY INCLUDE CARDIAC REMODELING (SIZE/SHAPE), ATHEROSCLEROSIS (CORONARY/VASCULAR CALCIFICATION), HEMODYNAMICS (AORTA/PULMONARY ARTERY, SIZE/VALVULAR CALCIUM), VISCERAL ADIPOSITY (LIVER AND EPICARDIAL ADIPOSE TISSUE), AND SARCOPENIA (SKELETAL MUSCLE, BONE DENSITY), COMBINED WITH CLINICAL FACTORS AND DEMOGRAPHICS, TO PREDICT FUTURE HF EVENTS. IN AIM 1, WE WILL DEVELOP AND VALIDATE AN AUTOMATED RADIOMIC EXTRACTION TOOL FROM CTCS. IN AIM 2, WE WILL DEVELOP AN HF RISK PREDICTION MODEL (CTCSHF) INCORPORATING CTCS-DERIVED RADIOMICS AND CLINICAL RISK FACTORS IN >160,000 PARTICIPANTS FROM 4 LARGE WELL-CHARACTERED PROSPECTIVE COHORTS WITH > 5000 INCIDENT HF EVENTS. IN AIM 3, WE WILL EXPLORE CTCSHF MODEL FAIRNESS ACROSS SOCIO-RACIAL GROUPS AND INVESTIGATE THE UTILITY OF FAIRNESS-AWARE CLINICO-RADIOMIC HF RISK MODELS (I.E., IN SUBGROUPS OF RACE AND SOCIOECONOMIC STATUS) IN IMPROVING ACCURACY. IMPROVED CHARACTERIZATION OF HF RISK WILL ADVANCE KNOWLEDGE OF CARDIOMETABOLIC DISEASE PHENOTYPES AND SUPPORT CLINICAL THERAPEUTIC DECISION-MAKING AND PATIENT COUNSELING FOR IMPROVED ADHERENCE.

Posted 12/12/24, 12:00 AM